Not much to get excited about. Its another expensi
Post# of 22454
Lots of limitations on its perrformance:
Performance of the Cue COVID-19 Test has only been established with Cue Sample Wand nasal swab samples and by dipping the Cue Sample Wand into a tube containing an individual nasal specimen in viral transport media (VTM).
• Detection of SARS-CoV-2 RNA may be affected by sample collection methods, patient factors (e.g., presence of symptoms), and/or stage of infection.
• A false negative result may occur if a sample is improperly collected or handled. False negative results may also occur if inadequate numbers of organisms are present in the sample.
• As with any molecular test, mutations within the target regions of SARS-CoV-2 could affect primer and/or probe binding resulting in failure to detect the presence of virus.
• This test cannot rule out diseases caused by other bacterial or viral pathogens.
• Analyte targets (viral nucleic acid) may persist in vivo, independent of virus viability.
Detection of analyte targets does not imply that the corresponding viruses are infectious or are the causative agents for clinical symptoms.
• Performance has not been established in asymptomatic individuals.
• This assay should not be used within 30 minutes of administering nasal or throat sprays.
NOTE: Testee could be most infectious when 'asymptomatic'. How the heck did this get approved?